Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 2/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.43 |
| ▸ | REN | P00797 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.42 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31188784 | 1.00 | DYRK1A (0.55) | DYRK1AATMARSLC6A4CLK1 | |
| SCHEMBL31607554 | 0.80 | TRIM24 (0.60) | ATMARRENTRIM24TRIM33 | |
| SCHEMBL2143637 | 0.80 | TRIM24 (0.60) | ATMARRENTRIM24TRIM33 | |
| SCHEMBL15692504 | 0.78 | REN (0.57) | ATMARRENTRIM24TRIM33 | |
| SCHEMBL5248011 | 0.77 | ATM (0.48) | ATMRENTRIM24TRIM33BRPF1 | |
| SCHEMBL16727192 | 0.77 | DYRK1A (0.53) | DYRK1AATMARRENTRIM24 | |
| SCHEMBL4078677 | 0.75 | DYRK1A (0.55) | DYRK1AATMARSLC6A4REN | |
| SCHEMBL3221554 | 0.75 | GPR84 (0.58) | ATMARSLC6A4RENTRIM24 | |
| SCHEMBL7089054 | 0.75 | REN (0.50) | ATMCLK1CDK5CDK5R1REN | |
| SCHEMBL28182493 | 0.75 | ATM (0.47) | ATMARRENTRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109670-A1 | METHOD FOR ARYL DEBROMINATION AND ACYLATION OF BROMINATED BENZO-FUSED NITROGEN HETEROCYCLE | Shanghai OuChem Bio-Technology Co., LTD (CN) | 2026-04-23 | — | — | US | disclosed |
| US-20250263491-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-08-21 | — | — | US | disclosed |
| CN-119059958-A | Method for aryl debromination acylation of bromobenzazepine compounds | 上海沃凯生物技术有限公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20230120736-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230114718-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-04-13 | — | — | US | disclosed |
| WO-2023018747-A1 | INHIBITORS OF HYPOXIA-INDUCIBLE FACTORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-02-16 | — | — | WO | disclosed |
| US-20200338209-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2020-10-29 | — | — | US | disclosed |
| CN-111620862-A | BCL-XL-inhibitory compounds and antibody drug conjugates including the same | 艾伯维公司 | 2020-09-04 | — | — | CN | disclosed |
| US-20200239553-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-20200147235-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2020-05-14 | — | — | US | disclosed |
| EP-1812388-A1 | SULFONAMIDE PERT-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | Decode Genetics (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1778233-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060142355-A1 | Carboxylic acid peri-substituted bicyclics for occlusive artery disease | DECODE CHEMISTRY, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| WO-2006044415-A2 | CARBOXYLIC ACID PERI - SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006044000-A1 | SULFONAMIDE PERT-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060079520-A1 | Sulfonamide peri-substituted bicyclics for occlusive artery disease | SAGA INVESTMENTS LLC | 2006-04-13 | — | — | US | disclosed |
| WO-2006019716-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| EP-0469833-B1 | N-Benzyl-Indoles, processes for their preparation and pharmaceutical compositions containing them | LILLY CO ELI (GB) | 1999-09-08 | — | — | EP | disclosed |
| US-5281593-A | Pharmaceuticals | LILLY INDUSTRIES LIMITED (GB) | 1994-01-25 | — | — | US | disclosed |
| EP-0469833-A1 | N-Benzyl-Indoles, processes for their preparation and pharmaceutical compositions containing them | LILLY INDUSTRIES LIMITED (GB) | 1992-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239553-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | BCL2, BCL2L10, BAX | DYRK1A 1175/4885ATM 1104/4885AR 3325/4885 |
| US-20230114718-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | DYRK1A 135/4885ATM 2357/4885AR 732/4885 |
| US-20200338209-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | DYRK1A 1856/4885ATM 4195/4885AR 2434/4885 |
| US-20250263491-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | DYRK1A 135/4885ATM 2357/4885AR 732/4885 |
| US-20230120736-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | DYRK1A 1798/4885ATM 4144/4885AR 3230/4885 |
| US-20200147235-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | DYRK1A 1798/4885ATM 4144/4885AR 3230/4885 |
| US-20260109670-A1 | METHOD FOR ARYL DEBROMINATION AND ACYLATION OF BROMINATED BENZO-FUSED NITROGEN HETEROCYCLE | NAT1, AADAC, NAA15 | DYRK1A 2283/4885ATM 393/4885AR 525/4885 |
| US-20060079520-A1 | Sulfonamide peri-substituted bicyclics for occlusive artery disease | PTGIS, PTGIR, PTGS2 | DYRK1A 4636/4885ATM 2587/4885AR 2292/4885 |
| US-20060142355-A1 | Carboxylic acid peri-substituted bicyclics for occlusive artery disease | PTGIS, PTGIR, PTGDR | DYRK1A 4678/4885ATM 3684/4885AR 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.